Evidence map›Paper›PMID 35148845›Full record

ArticleStem cell reports2022

FOXG1 dose tunes cell proliferation dynamics in human forebrain progenitor cells.

Nuwan C Hettige, Huashan Peng, Hanrong Wu, Xin Zhang, Volodymyr Yerko, Ying Zhang, Malvin Jefri, Vincent Soubannier, Gilles Maussion, Shaima Alsuwaidi and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Nuwan C HettigeDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Huashan PengPsychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Hanrong WuPsychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Xin ZhangPsychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Volodymyr YerkoDepartment of Psychiatry, McGill University, Montreal, QC H3A 1A1, Canada.
Ying ZhangPsychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Malvin JefriPsychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada; Integrated Program in Neuroscience, McGill University, Montreal, QC H3A 2B4, Canada.
Vincent SoubannierMcGill Parkinson Program and Neurodegenerative Diseases Group, Montreal Neurological Institute, Department of Neurology and Neurosurgery, Montreal, QC H3A 2B4, Canada; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Gilles MaussionMcGill Parkinson Program and Neurodegenerative Diseases Group, Montreal Neurological Institute, Department of Neurology and Neurosurgery, Montreal, QC H3A 2B4, Canada; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Shaima AlsuwaidiDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Anjie NiDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Cecilia RochaThe Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Jeyashree KrishnanInstitute for Computational Biomedicine, Aachen University, Pauwelsstraße 19, 52074 Aachen, Germany.
Vincent McCartyDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Lilit AntonyanDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada.
Andreas SchuppertInstitute for Computational Biomedicine, Aachen University, Pauwelsstraße 19, 52074 Aachen, Germany.
Gustavo TureckiDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Department of Psychiatry, McGill University, Montreal, QC H3A 1A1, Canada; Integrated Program in Neuroscience, McGill University, Montreal, QC H3A 2B4, Canada.
Edward A FonMcGill Parkinson Program and Neurodegenerative Diseases Group, Montreal Neurological Institute, Department of Neurology and Neurosurgery, Montreal, QC H3A 2B4, Canada.
Thomas M DurcanMcGill Parkinson Program and Neurodegenerative Diseases Group, Montreal Neurological Institute, Department of Neurology and Neurosurgery, Montreal, QC H3A 2B4, Canada; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada.
Carl ErnstDepartment of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada; Psychiatric Genetics Group, Douglas Mental Health University Institute, 6875 Boulevard LaSalle, Montreal, QC H4H 1R3, Canada; Department of Psychiatry, McGill University, Montreal, QC H3A 1A1, Canada; Integrated Program in Neuroscience, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: carl.ernst@mcgill.ca.
McGill University · CADouglas Mental Health University Institute · CAMontreal Neurological Institute and Hospital · CARWTH Aachen University · DE

Funding

CIHR FDN-154301
6 · The paper itself

Abstract

Heterozygous loss-of-function mutations in Forkhead box G1 (FOXG1), a uniquely brain-expressed gene, cause microcephaly, seizures, and severe intellectual disability, whereas increased FOXG1 expression is frequently observed in glioblastoma. To investigate the role of FOXG1 in forebrain cell proliferation, we modeled FOXG1 syndrome using cells from three clinically diagnosed cases with two sex-matched healthy parents and one unrelated sex-matched control. Cells with heterozygous FOXG1 loss showed significant reduction in cell proliferation, increased ratio of cells in G0/G1 stage of the cell cycle, and increased frequency of primary cilia. Engineered loss of FOXG1 recapitulated this effect, while isogenic repair of a patient mutation reverted output markers to wild type. An engineered inducible FOXG1 cell line derived from a FOXG1 syndrome case demonstrated that FOXG1 dose-dependently affects all cell proliferation outputs measured. These findings provide strong support for the critical importance of FOXG1 levels in controlling human brain cell growth in health and disease.

Indexed as

Forkhead Transcription FactorsNerve Tissue ProteinsCell ProliferationHumansProsencephalonStem CellsSyndromeForkhead Transcription FactorsFOXG1 protein, humanNerve Tissue ProteinsBF-1cell proliferationciliaforebrainFOXG1iPSCneural progenitor cellneurodevelopment

Identifiers

PMID35148845
PMCPMC9040178
OpenAlexW4211159670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.